[1] Cardoso CRL, Salles GC, Leite NC, Salles GF. Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2019;18(1); doi: 10.1186/s12933-019-0809-1.
[2] Centurión OA. Carotid Intima-Media Thickness as a Cardiovascular Risk Factor and Imaging Pathway of Atherosclerosis. Crit Pathw Cardiol. 2016;15(4):152-160; doi: 10.1097/hpc.0000000000000087.
[3] Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93-111; quiz 189-90; doi: 10.1016/j.echo.2007.11.011.
[4] Van Montfort R, Slingsby C, Vierling E. Structure and function of the small heat shock protein/alpha-crystallin family of molecular chaperones. Advances in protein chemistry. 2001;59:105-56; doi: 10.1016/s0065-3233(01)59004-x.
[5] Beck FX, Neuhofer W, Müller E. Molecular chaperones in the kidney- distribution, putative roles, and regulation. Am J Physiol Renal Physiol. 2000;279(2):F203-15; doi: 10.1152/ajprenal.2000.279.2.F203.
[6] Kim HJ, Hwang NR, Lee KJ. Heat shock responses for understanding diseases of protein denaturation. Molecules and cells. 2007;23(2):123-31.
[7] De Maio A. Heat shock proteins: facts, thoughts, and dreams. Shock. 1999;11(1):1-12; doi: 10.1097/00024382-199901000-00001.
[8] Ranford JC, Henderson B. Chaperonins in disease: mechanisms, models, and treatments. Molecular pathology. 2002;55(4):209-13; doi: 10.1136/mp.55.4.209.
[9] Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nature cell biology. 2000;2(9):645-652; doi: 10.1038/35023595.
[10] Tian X, Zhao L, Song X, Yan Y, Liu N, Li T,et al. HSP27 Inhibits Homocysteine-Induced Endothelial Apoptosis by Modulation of ROS Production and Mitochondrial Caspase-Dependent Apoptotic Pathway. BioMed research international. 2016;2016:1-9; doi: 10.1155/2016/4847874
[11] Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, et al. Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. British journal of cancer. 2012;107(1):63-70; doi: 10.1038/bjc.2012.188.
[12] Beck FX, Neuhofer W, Müller E. Molecular chaperones in the kidney: distribution, putative roles, and regulation. American journal of physiology. Renal physiology. 2000;279(2):F203-215; doi: 10.1152/ajprenal.2000.279.2.f203.
[13] Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis & tissue repair. 2012;5(1):7; doi: 10.1186/1755-1536-5-7.
[14] Smoyer WE, Gupta A, Mundel P, Ballew JD, Welsh MJ. Altered expression of glomerular heat shock protein 27 in experimental nephrotic syndrome. The Journal of clinical investigation. 1996;97(12):2697-2704; doi: 10.1172/jci118723.
[15] Smoyer WE, Ransom RF. Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2002;16(3):315-326; doi: 10.1096/fj.01-0681com.
[16] Zhang S, Hu Y, Huang Y, Xu H, Wu G, Dai H. Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer. Oncology letters. 2015;9(6):2572-2576; doi: 10.3892/ol.2015.3073.
[17] Batulan Z, Pulakazhi Venu VK, Li Y, Koumbadinga G, Alvarez-Olmedo DG, Shi C,et al. Extracellular Release and Signaling by Heat Shock Protein 27: Role in Modifying Vascular Inflammation. Frontiers in immunology. 2016;7:285; doi: 10.3389/fimmu.2016.00285.
[18] Trott D, McManus CA, Martin JL, Brennan B, Dunn MJ, Rose ML. Effect of phosphorylated hsp27 on proliferation of human endothelial and smooth muscle cells. Proteomics. 2009;9(12):3383-94; doi: 10.1002/pmic.200800961.
[19] Bruxel MA, Tavares AMV, Zavarize Neto LD, de Souza Borges V, Schroeder HT, Bock PM, et al. Chronic whole-body heat treatment relieves atherosclerotic lesions, cardiovascular and metabolic abnormalities, and enhances survival time restoring the anti-inflammatory and anti-senescent heat shock response in mice. Biochimie. 2019;156:33-46; doi: 10.1016/j.biochi.2018.09.011.
[20] Seibert TA, Hibbert B, Chen YX, Rayner K, Simard T, Hu T, et al. Serum heat shock protein 27 levels represent a potential therapeutic target for atherosclerosis: observations from a human cohort and treatment of female mice. Journal of the American College of Cardiology. 2013;62(16): 1446-1454; doi: 10.1016/j.jacc.2013.05.041.
[21] Rayner K, Chen YX, McNulty M, Simard T, Zhao X, Wells DJ, et al. Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A. Circulation research. 2008;103(2):133-41; doi: 10.1161/circresaha.108.172155.
[22] Cuerrier CM, Chen YX, Tremblay D, Rayner K, McNulty M, Zhao X, et al. Chronic over-expression of heat shock protein 27 attenuates atherogenesis and enhances plaque remodeling: a combined histological and mechanical assessment of aortic lesions. PloS one. 2013;8(2):e55867; doi: 10.1371/journal.pone.0055867.
[23] Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004;110(15):2216-9; doi: 10.1161/01.cir.0000136814.87170.b1.
[24] Martin-Ventura JL, Nicolas V, Houard X, Blanco-Colio LM, Leclercq A, Egido J, et al. Biological significance of decreased HSP27 in human atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(6):1337-43; doi: 10.1161/01.atv.0000220108.97208.67
[25] Liang W, Ward LJ, Karlsson H, Ljunggren SA, Li W, Lindahl M, et al. Distinctive proteomic profiles among different regions of human carotid plaques in men and women. Scientific Reports. 2016;6:26231; doi: 10.1038/srep26231.
[26] Miller H, Poon S, Hibbert B, Rayner K, Chen YX, O'Brien ER. Modulation of estrogen signaling by the novel interaction of heat shock protein 27, a biomarker for atherosclerosis, and estrogen receptor beta: mechanistic insight into the vascular effects of estrogens. Arteriosclerosis, thrombosis, and vascular biology. 2005;25(3):e10-4; doi: 10.1161/01.atv.0000156536.89752.8e.
[27] Lepedda AJ, Cigliano A, Cherchi GM, Spirito R, Maggioni M, Carta F, et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis. 2009;203(1):112-8. ; doi: 10.1016/j.atherosclerosis.2008.07.001.
[28] Park HK, Park EC, Bae SW, Park MY, Kim SW, Yoo HS, et al. Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. Circulation. 2006;114(9):886-93; doi: 10.1161/circulationaha.105.541219.
[29] Zhang HL, Jia KY, Sun D, Yang M. Protective effect of HSP27 in atherosclerosis and coronary heart disease by inhibiting reactive oxygen species. Journal of cellular biochemistry. 2019;120(3):2859-2868; doi: 10.1002/jcb.26575.
[30] Lu B, Yang Y, Yang Z, Feng X, Wang X, Zhang Z, et al. Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity. Cardiovasc Diabetol. 2010;9:92; doi: 10.1186/1475-2840-9-92.
[31] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9; doi: 10.1007/bf00280883.
[32] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2002;39(2 Suppl 1):S1-266; doi: 10.1053/ajkd.2002.30939.
[33] Jakhotia S, Sivaprasad M, Shalini T, Reddy PY, Viswanath K, Jakhotia K, et al. Circulating levels of Hsp27 in microvascular complications of diabetes: Prospects as a biomarker of diabetic nephropathy. Journal of diabetes and its complications. 2018;32(2):221-225; doi: 10.1016/j.jdiacomp.2017.10.004.
[34] Balakumar P, Maung-U K, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacological research. 2016;113:600-609; doi: 10.1016/j.phrs.2016.09.040.
[35] Rehman K, Akash MSH. Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus: How Are They Interlinked? Journal of cellular biochemistry. 2017;118(11):3577-3585; doi: 10.1002/jcb.26097.
[36] Taleb S. Inflammation in atherosclerosis. Archives of cardiovascular diseases. 2016;109(12):708-715; doi: 10.1016/j.acvd.2016.04.002
[37] Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative Stress in Atherosclerosis. Current atherosclerosis reports. 2017;19(11):42; doi: 10.1007/s11883-017-0678-6.
[38] Förstermann U, Xia N, Li H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circulation research. 2017;120(4):713-735; doi: 10.1161/circresaha.116.309326.
[39] Perrotta I, Aquila S. The role of oxidative stress and autophagy in atherosclerosis. Oxidative medicine and cellular longevity. 2015;2015:1-10; doi: 10.1155/2015/130315.
[40] Abaspour AR, Taghikhani M, Parizadeh SMR, Seyedi SMR, Ghazizadeh H, Kazemi E, et al. HSP27 expression in the human peripheral blood mononuclear cells as an early prognostic biomarker in coronary artery disease patients. Diabetes & metabolic syndrome. 2019;13(3):1791-1795; doi: 10.1016/j.dsx.2019.04.010.
[41] Balta S, Aparci M, Ozturk C, Yildirim AO, Demir M, Celik T. Carotid intima media thickness and subclinical early atherosclerosis. International journal of cardiology. 2016;203:1146; doi: 10.1016/j.ijcard.2015.11.025.
[42] Najemnikova E, Rodgers CD, Locke M. Altered heat stress response following streptozotocin-induced diabetes. Cell stress & chaperones. 2007;12(4):342-352; doi: 10.1379/csc-292.
[43] Shi C, Ulke-Lemée A, Deng J, Batulan Z, O'Brien ER. Characterization of heat shock protein 27 in extracellular vesicles: a potential anti-inflammatory therapy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2019;33(2):1617-1630; doi: 10.1096/fj.201800987r.
[44] Pulakazhi Venu VK, Adijiang A, Seibert T, Chen YX, Shi C, Batulan Z, et al. Heat shock protein 27-derived atheroprotection involves reverse cholesterol transport that is dependent on GM-CSF to maintain ABCA1 and ABCG1 expression in ApoE(-/-) mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2017;31(6):2364-2379; doi: 10.1096/fj.201601188r.
[45] De AK, Kodys KM, Yeh BS, Miller-Graziano C. Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. Journal of immunology. 2000;165(7):3951-8; doi: 10.4049/jimmunol.165.7.3951.
[46] Jin C, Phillips VL, Williams MJ, van Rij AM, Jones GT. Plasma heat shock protein 27 is associated with coronary artery disease, abdominal aortic aneurysm and peripheral artery disease. SpringerPlus. 2014;3:635; doi: 10.1186/2193-1801-3-635.
[47] Jaroszyński A, Jaroszyńska A, Zaborowski T, Drelich-Zbroja A, Zapolski T, Dąbrowski W. Serum heat shock protein 27 levels predict cardiac mortality in hemodialysis patients. BMC nephrology. 2018;19(1):359; doi: 10.1186/s12882-018-1157-1.
[48] Osterloh A, Breloer M. Heat shock proteins: linking danger and pathogen recognition. Medical microbiology and immunology. 2008;197(1):1-8; doi: 10.1007/s00430-007-0055-0.
[49] Lamfers ML, Grimbergen JM, Aalders MC, Havenga MJ, de Vries MR, Huisman LG, et al. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circulation research. 2002;91(10):945-952; doi: 10.1161/01.res.0000041418.51906.57
[50] Choi SH, Lee HJ, Jin YB, Jang J, Kang GY, Lee M, et al. MMP9 processing of HSPB1 regulates tumor progression. PloS one. 2014;9(1):e85509; doi: 10.1371/journal.pone.0085509.